← All trials
NCT05243797
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2022
- Primary completion
- Oct 31, 2028
- Completion date
- Dec 31, 2031
- First posted
- Feb 17, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 1500
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Myeloma NetworkLead sponsor
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.